

Semaglutide for weight loss: Does semaglutide use increase the risk of depression or suicidality?

James Frobb – Pharm 535 Fall 2024

Reference List

- Wang, W., Volkow, N.D., Berger, N.A., et al. (2024). Association of semaglutide with risk of suicidal ideation in a real-world cohort. *Nature Medicine*, 30, 168–176. <https://doi.org/10.1038/s41591-023-02672-2>
- Wadden, T.A., et al. (2024). Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. *JAMA Internal Medicine*. <https://doi.org/10.1001/jamainternmed.2024.4346>
- Blasco, B. V., García-Jiménez, J., Bodoano, I., & Gutiérrez-Rojas, L. (2020). Obesity and Depression: Its Prevalence and Influence as a Prognostic Factor: A Systematic Review. *Psychiatry investigation*, 17(8), 715–724. <https://doi.org/10.30773/pi.2020.0099>
- Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA*, 325(14), 1414–1425. doi:10.1001/jama.2021.3224
- Link to PHQ-9 Template: https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/depression_patient_health_questionnaire.pdf
- Clinical Review Report: Insulin Degludec (Tresiba): (Novo Nordisk Canada Inc): Indication: For once-daily treatment of adults with diabetes mellitus to improve glycemic control [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec. Appendix 4, Validity of Outcome Measures. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK533976/>